A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

Phase 2 Not yet recruiting 23 enrolled Shanxi Province Cancer Hospital

NaSingle-groupOpen-labelTreatment

Evaluation the efficacy and safety of Zanubrutinib + R-CHOP/R-DHAP for the treatment mantle cell lymphoma.

Evaluation	Drug	Modality	Dose	Route
Subject	Zanubrutinib	Small molecule	160 mg	Oral
Background	Cisplatin	Other / unclassified	100 mg/m2	Intravenous
Background	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Background	Cytarabine	Small molecule	2 g	Intravenous
Background	Dexamethasone	Small molecule	40 mg	Oral
Background	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	100 mg	Oral
Background	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Background	Vincristine	Small molecule	1.4 mg/m2	Intravenous